Marufa Akter out of New Zealand tour: bone erosion in foot, four weeks of rest, no fixed return date

Dhaka. Marufa Akter, among Bangladesh women's frontline fast bowlers, has been ruled out of the white-ball series against New Zealand. Following the detection of bone erosion in the fifth metatarsal of her foot, she has been placed in an Aircast brace, with medical advice prescribing four weeks of complete rest and no weight-bearing on the affected foot. A senior Bangladesh Cricket Board (BCB) official closely associated with the board's women's wing confirmed that Marufa is unavailable for the tour, but the board has not announced any fixed timeline for her return. The location of the injury matters. The problem is understood to be near the base of the fifth metatarsal on the outer side of the foot — a region sports medicine treats as a watershed area, where limited blood supply slows bone healing and raises the risk of recurrence. The Aircast brace is the primary intervention so far, immobilising the foot and shielding the injured area from load. According to the board, surgery has not been discussed and a conservative treatment path has been chosen. The sequence of events runs roughly as follows. Before the Australia tour, Marufa was given an injection for the pain, which did not produce the expected relief, and she did not play the final match of that tour. Four weeks of rest then began in early November. She was expected to be able to walk normally in the first week of December — consistent with the four-week calculation. The team departs Dhaka on 4 December, precisely at the point when she would only just be mobile. The New Zealand tour comprises three ODIs and three T20Is. The board official's statement is unambiguous. Speaking on condition of anonymity, he said, "Marufa is unavailable for the New Zealand tour." He added that the board does not want to rush her back because of the risk of the pain recurring, and that the player would be given adequate time. Notably, the quotes dwell on why she is not being played rather than on when she will return. In practical terms, that makes the absence open-ended. On sourcing, the biggest weakness of this story is that every key claim rests on a single unnamed official. There has been no formal BCB release, no comment from the team medical staff, and no statement from Marufa herself. The medical details — the injection failing to work, her missing the last Australia match — are not corroborated by the medical team. They should be treated at the level of reporter's information, not established fact. A second major question is whether she was in the original squad for the New Zealand tour. Language of the 'out of the tour' variety implies she had been picked, but there is no independent confirmation. If she was never selected, the entire unavailability framing weakens. The related question — who comes in for her — goes unanswered throughout. No replacement seamer has been named, even though that is the most essential information in a story about the premier fast bowler being ruled out. The match-by-match schedule of the tour is also missing. Only the departure date (4 December) is given, which makes it impossible to work out when the first match is or which fixture would be her earliest possible return opportunity. Nor is it clear whether the board is targeting a specific tournament in planning her rehabilitation. There is no word either on whether any other player's fitness is in question. Medical background (this is general sports medicine knowledge, not part of the report): the base of the fifth metatarsal is known for Jones fractures and stress fractures. Bone erosion generally points to chronic stress response or an inflammatory process rather than an acute fracture, which is why bracing, offloading and time are a rational course. One caution is warranted — a full four weeks of bed rest is relatively aggressive for a metatarsal stress injury; standard protocol is non-weight-bearing with a brace. It is better understood as offloading. On competitive impact, the available information is thin. There is no indication of how many overs Marufa has bowled in recent series, how deep Bangladesh's pace reserves are, what the series is worth in points, or how her absence would affect the ODI and T20I sides differently. The story therefore answers 'what happened' but not 'how serious it is'. The things to watch are clear. The official BCB squad announcement will settle whether she was in the original list and who replaces her; the detailed schedule will reveal her likely return window; any future mention of surgery would signal an escalation; and independent confirmation of the injection and its ineffectiveness should come from Bangladeshi local media. Until then, the story should be cited as 'according to an unnamed BCB official', not as established fact.